Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.67), $0.27 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $9.69 million versus the consensus estimate of $10.1 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.